The Citizens Commission on Human Rights International (CCHR), a 57-year mental health watchdog, warns that vulnerable elderly residents in U.S. nursing homes continue to face serious risks from antipsychotics despite decades of federal investigations and repeated calls for reform. The U.S. Department of Health and Human Services Office of Inspector General recently issued two reports examining psychotropic drugging in nursing homes, finding that facilities routinely administered antipsychotics—drugs not FDA-approved for dementia and linked to increased mortality—to control resident behavior while failing to implement required safeguards.
In a review of 40 Centers for Medicare and Medicaid Services inspections, the OIG stated that “the inappropriate use of antipsychotic drugs in nursing homes has been a longstanding concern for Congress and others.” The reports exposed a deliberate tactic: some nursing homes misdiagnose residents with schizophrenia to bypass accountability and artificially improve public quality ratings. Current penalties—capped at $1,000–$5,000 for false certifications—are inadequate. In 2023, although HHS identified serious problems with inappropriate antipsychotic use and inaccurate schizophrenia diagnoses, the agency did not impose substantial financial penalties.
Antipsychotics carry well-documented dangers for elderly patients. In 2005, the FDA issued a black-box warning for their use in dementia patients due to elevated death risks. In 2007, FDA senior drug safety official Dr. David Graham warned that at least 15,000 nursing home residents die annually from these drugs. A 2024 American Association of Retired Persons report found that in people with dementia aged 50 and older, antipsychotics more than doubled the risk of pneumonia—the leading cause of death in this population—while also increasing risks of stroke, acute kidney injury, blood clots, bone fractures, heart attack, and heart failure.
The problem extends decades: In 2011, the OIG reported that 88% of antipsychotics were prescribed off-label to elderly dementia patients despite FDA warnings. From 2019–2020, roughly 20% of skilled nursing facility residents—about 298,650 people weekly—received antipsychotics. A House Ways and Means report described the situation as “one of patient harm, inadequate oversight, and insufficient staffing.” CCHR urges Congress, CMS, and state authorities to impose substantial penalties on prescribers and facilities and to prioritize non-drug alternatives for behavioral care.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/247pressrelease-2026-4-20-cchr-says-new-oig-report-exposes-repeat-of-20-year-old-findings-us-nursing-homes-drugging-elderly-with-antipsychotics